Overview

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-02-10
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to demonstrate the bioequivalence (BE) of a single subcutaneous (SC) dose of lecanemab via vial and AI in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.